Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

2 years ago

IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on…

Omega Therapeutics Announces Updates to its Board of Directors

2 years ago

Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed…

Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock

2 years ago

SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development…

StateHouse Launches Intercanopy Lighting Validation Study

2 years ago

Commercial cannabis cultivator partners with other growers, Grow Light Design and The Cannabis Research Coalition to examine the impact of…

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

2 years ago

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters…

Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer

2 years ago

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of…

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

2 years ago

Topline Results Expected 1H 2024WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the…

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

2 years ago

19.3 month significant survival difference for CNM-Au8® treated participants versus placebo52% significant decreased risk of ALS clinical worsening events Over…

Entrada Therapeutics to Present at Upcoming Investor Conferences

2 years ago

BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives…

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

2 years ago

TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed…